A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT02399072 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 202
Last updated 2019-08-09
Summary
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study also will generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling 200 participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 60 months.
Conditions
Interventions
- OTHER
-
No intervention
No intervention administered in this study
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-03-30
- Primary Completion
- 2018-02-08
- Completion
- 2018-02-08
Countries
- United States
- Argentina
- Australia
- Brazil
- Canada
- France
- Germany
- Hungary
- Italy
- Poland
- Spain
- United Kingdom
Study Locations
More Related Trials
-
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
NCT02745119 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
NCT03972709 ·Status: TERMINATED ·Phase: PHASE2
-
Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
NCT01675947 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT03295877 ·Status: COMPLETED ·Phase: PHASE1
-
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
NCT01310686 ·Status: UNKNOWN
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773 ·Status: RECRUITING
-
Genetic Study of Age-Related Macular Degeneration
NCT00357578 ·Status: COMPLETED
-
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
NCT01255462 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT04607148 ·Status: TERMINATED ·Phase: PHASE2
-
Recurrent Neovascular Age-related Macular Degeneration After Therapy Suspension
NCT04659512 ·Status: COMPLETED
-
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
NCT04002310 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
NCT01229215 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT04615325 ·Status: COMPLETED ·Phase: PHASE1
-
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
NCT04437368 ·Status: TERMINATED ·Phase: PHASE2
-
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
NCT03699618 ·Status: TERMINATED
-
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
NCT05392751 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT01024998 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148 ·Status: RECRUITING ·Phase: PHASE2
-
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
NCT03468296 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549 ·Status: RECRUITING ·Phase: PHASE2
-
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT06817343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
NCT03894020 ·Status: TERMINATED
-
Study of NGM621 in Participants With Geographic Atrophy
NCT04014777 ·Status: COMPLETED ·Phase: PHASE1